Cell models for Down syndrome-Alzheimer’s disease research

Wu, Yixing; West, Nicole; Bhattacharyya, Anita; Wiseman, Frances K.

doi:10.1042/ns20210054

Cited by 4 publications

(4 citation statements)

References 295 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human DS iPSC models have contributed significant knowledge of the pathophysiological mechanisms of DS. The majority of current DS iPSC research has generated cells of the nervous system to decipher mechanisms of intellectual disability underlying DS ( Wu et al, 2022 ).…”

Section: Resource Detailsmentioning

confidence: 99%

Generation of two induced pluripotent stem cell lines from patients with Down syndrome

Zhu,

Liu,

et al. 2023

Stem Cell Research

View full text Add to dashboard Cite

Section: Resource Detailsmentioning

confidence: 99%

Generation of two induced pluripotent stem cell lines from patients with Down syndrome

Zhu,

Liu,

et al. 2023

Stem Cell Research

View full text Add to dashboard Cite

“…There has been much work on animal models [ 117 , 118 , 119 , 120 ], cellular models, [ 121 , 122 , 123 , 124 , 125 ] and computational/mathematical models [ 126 , 127 , 128 , 129 ] of dementia. However, none of these has captured all of the critical elements involved in the pathogenesis of the dementias and so cannot generate the sought-after answers.…”

Section: Specific Challengesmentioning

confidence: 99%

A Perspective: Challenges in Dementia Research

Stecker

2022

Medicina

View full text Add to dashboard Cite

Although dementia is a common and devastating disease that has been studied intensely for more than 100 years, no effective disease modifying treatment has been found. At this impasse, new approaches are important. The purpose of this paper is to provide, in the context of current research, one clinician’s perspective regarding important challenges in the field in the form of specific challenges. These challenges not only illustrate the scope of the problems inherent in finding treatments for dementia, but can also be specific targets to foster discussion, criticism and new research. One common theme is the need to transform research activities from small projects in individual laboratories/clinics to larger multinational projects, in which each clinician and researcher works as an integral part. This transformation will require collaboration between researchers, large corporations, regulatory/governmental authorities and the general population, as well as significant financial investments. However, the costs of transforming the approach are small in comparison with the cost of dementia.

show abstract

“…Induced pluripotent stem cell (iPSC) technology has emerged as a valuable tool for studying the cellular and molecular pathologies in specific cell types affected by DS (Wu et al, 2022b). These iPSCs can be derived from somatic cells such as fibroblasts from DS patients or healthy humans (Cypris et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Realizing the potential of exploiting human IPSCs and their derivatives in research of Down syndrome

WANG,

NI,

LIU

et al. 2023

BIOCELL

View full text Add to dashboard Cite

Down syndrome (DS) is a genetic condition characterized by intellectual disability, delayed brain development, and early onset Alzheimer's disease. The use of primary neural cells and tissues is important for understanding this disease, but there are ethical and practical issues, including availability from patients and experimental manipulability.Moreover, there are significant genetic and physiological differences between animal models and humans, which limits the translation of the findings in animal studies to humans. Advancements in induced pluripotent stem cells (iPSC) technology have revolutionized DS research by providing a valuable tool for studying the cellular and molecular pathologies associated with DS. Induced pluripotent stem cells derived from cells obtained from DS patients contain the patient's entire genome including trisomy 21. Trisomic iPSCs as well as their derived cells or organoids can be useful for disease modeling, investigating the molecular mechanisms, and developing potential strategies for treating or alleviating DS. In this review, we focus on the use of iPSCs and their derivatives obtained from DS individuals and healthy humans for DS research. We summarize the findings from the past decade of DS studies using iPSCs and their derivatives. We also discuss studies using iPSC technology to investigate DS-associated genes (e.g., APP, OLIG1, OLIG2, RUNX1, and DYRK1A) and abnormal phenotypes (e.g., dysregulated mitochondria and leukemia risk). Lastly, we review the different strategies for mitigating the limitations of iPSCs and their derivatives, for alleviating the phenotypes, and for developing therapies.

show abstract

Cell models for Down syndrome-Alzheimer’s disease research

Cited by 4 publications

References 295 publications

Generation of two induced pluripotent stem cell lines from patients with Down syndrome

Generation of two induced pluripotent stem cell lines from patients with Down syndrome

A Perspective: Challenges in Dementia Research

Realizing the potential of exploiting human IPSCs and their derivatives in research of Down syndrome

Contact Info

Product

Resources

About